Myriad Genetics shares are trading lower after the company reported Q1 EPS of $0.08 compared to the $0.32 estimate and worse-than-expected Q1 sales results. The company also issued Q2 and FY20 EPS and sales guidance below analyst estimates.
Benzinga Newsdesk